UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                   FORM 10-QSB

(Mark  One)

[X]  QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
     EXCHANGE ACT OF 1934

     For  the  quarterly  period  ended  March  31,  2006

                                       OR

[ ]  TRANSITION REPORT PURUSANT TO SECTION 13 OR 15(d) OF THE SECURITIES
     EXCHANGE ACT OF 1934

                        Commission file number 33-19598-D

                                    VYTA CORP
                                    ---------
        (Exact name of small business issuer as specified in its charter)

               Nevada                                       84-0992908
               ------                                       ----------
  (State or other jurisdiction of                     (I.R.S. employer
   incorporation or organization)                      identification  number)

                           370 17th Street, Suite 3640
                             Denver, Colorado 80202

                    (Address of principal executive offices)

         Issuer's telephone number, including area code:  (303) 592-1010

                          NanoPierce Technologies, Inc.
   (Former name, former address or former fiscal year, if changed since last
                                    report)

Check  whether  the  issuer  (1)  has  filed all reports required to be filed by
Section 13(a) or 15(d) of the Securities Exchange Act of 1934 during the past 12
months (or for such shorter period that the registrant was required to file such
reports),  and  (2) has been subject to such filing requirements for the past 90
days.     Yes  X   No
              ---     ---

Indicate  by check mark whether the registrant is a shell company (as defined in
Rule  12b-2  of  the  Exchange  Act).     Yes      No  X
                                              ---     ---

State the number of shares outstanding of each of the issuer's classes of common
equity,  as  of  the  latest  practicable  date:

As  of  May 19, 2006 there were 22,493,512 shares of the registrant's sole class
of  common  shares  outstanding.

Transitional  Small  Business  Disclosure  Format     Yes      No  X
                                                          ---     ---


<PAGE>
<TABLE>
<CAPTION>
PART I - FINANCIAL INFORMATION

Item 1.    Financial Statements(Unaudited)                                        Page
                                                                                  ----
<S>        <C>                                                                    <C>
           Report of Independent Registered Public Accounting Firm                 F-1

           Condensed Consolidated Balance Sheet -March 31, 2006                    F-2

           Condensed Consolidated Statements of Operations  -
               Three and Nine months ended March 31, 2006 and 2005                 F-3

           Condensed Consolidated Statements of Comprehensive
               Loss - Three and Nine months ended March 31, 2006 and 2005          F-4

           Condensed Consolidated Statement of Changes in Shareholders'
               Equity -Nine months ended March 31, 2006                            F-5

           Condensed Consolidated Statements of Cash Flows -
               Nine months ended March 31, 2006 and 2005                           F-7

           Notes to Condensed Consolidated Financial Statements                    F-9

Item 2.    Management's Discussion and Analysis                                    1

Item 3.    Controls and Procedures                                                 4

PART II - OTHER INFORMATION

Item 1.    Legal Proceedings

Item 2.    Unregistered Sales of Equity Securities and Use of Proceeds             6

Item 3.    Defaults Upon Senior Securities - Not Applicable

Item 4.    Submission of Matters to a Vote of Security Holders - Not Applicable

Item 5.    Other Information - Not Applicable

Item 6.    Exhibits                                                                8

SIGNATURES                                                                         9
</TABLE>


<PAGE>
PART I - FINANCIAL INFORMATION

Item 1. Financial Statements


             REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
             -------------------------------------------------------


Board of Directors
Vyta Corp

We  have  reviewed the accompanying condensed consolidated balance sheet of Vyta
Corp  (formerly  known as NanoPierce Technologies, Inc.)  and subsidiaries as of
March  31, 2006, the related condensed consolidated statements of operations and
comprehensive  loss  for  the three-month and nine-month periods ended March 31,
2006  and  2005,  the  condensed  consolidated  statements of cash flows for the
nine-month periods ended March 31, 2006 and 2005, and the condensed consolidated
statement  of  changes  in  shareholders' equity for the nine-month period ended
March  31,  2006.  These interim condensed consolidated financial statements are
the  responsibility  of  the  Company's  management.

We  conducted our reviews in accordance with the standards of the Public Company
Accounting  Oversight  Board  (United  States).  A  review  of interim financial
information  consists  principally  of applying analytical procedures and making
inquiries  of  persons  responsible for financial and accounting matters.  It is
substantially less in scope than an audit conducted in accordance with standards
of  the Public Company Accounting Oversight Board (United States), the objective
of  which  is  the  expression  of an opinion regarding the financial statements
taken  as  a  whole.  Accordingly,  we  do  not  express  such  an  opinion.

Based on our reviews, we are not aware of any material modifications that should
be  made to the accompanying interim condensed consolidated financial statements
for  them  to  be in conformity with accounting principles generally accepted in
the  United  States  of  America.


/s/ GHP HORWATH, P.C.

Denver, Colorado
May  16,  2006


                                     F-1
<PAGE>
<TABLE>
<CAPTION>
                            VYTA CORP AND SUBSIDIARIES
                 (FORMERLY KNOWN AS NANOPIERCE TECHNOLOGIES, INC.)
                       Condensed Consolidated Balance Sheet
                                  March 31, 2006
                                    (Unaudited)

                                      Assets
                                      ------
<S>                                                                  <C>
Current assets:
  Cash and cash equivalents                                          $    125,741
  Interest and other receivables                                            1,586
  Prepaid expenses                                                         39,368
  Note receivable, related party (Note 2)                               1,005,078
                                                                     -------------
    Total current assets                                                1,171,773
                                                                     -------------

Property and equipment:
  Office equipment and furniture                                           66,357
  Less accumulated depreciation                                           (54,793)
                                                                     -------------
                                                                           11,564
                                                                     -------------

Other assets:
  Interest receivable                                                      13,844
  Deposits and other                                                       19,330
  Notes receivable, affiliate (Note 2)                                    875,000
  Investments in affiliates (Note 3)                                    1,229,746
                                                                     -------------
                                                                        2,149,484
                                                                     -------------

      Total assets                                                   $  3,321,257
                                                                     =============

                       Liabilities and Shareholders' Equity
                       ------------------------------------

Current liabilities:
  Accounts payable                                                   $    161,032
  Accrued liabilities                                                      10,427
                                                                     -------------
    Total liabilities  (all current)                                      171,459
                                                                     -------------

Commitments and contingencies (Notes 4, 5 and 8)

Shareholders' equity (Note 7):
  Preferred stock; $0.0001 par value; 5,000,000 shares authorized;
    none issued and outstanding
  Common stock; $0.0001 par value; 200,000,000 shares authorized;
    22,493,512 shares issued and outstanding                                2,250
  Additional paid-in capital                                           28,015,896
  Accumulated other comprehensive income                                  123,228
  Accumulated deficit                                                 (24,991,576)
                                                                     -------------
    Total shareholders' equity                                          3,149,798
                                                                     -------------

      Total liabilities and shareholders' equity                     $  3,321,257
                                                                     =============

See notes to condensed consolidated financial statements.
</TABLE>


                                     F-2
<PAGE>
<TABLE>
<CAPTION>
                                 VYTA CORP AND SUBSIDIARIES
                     (FORMERLY KNOWN AS NANOPIERCE TECHNOLOGIES, INC.)
                      Condensed Consolidated Statements of Operations
                                        (Unaudited)

                                             Three Months Ended     Nine Months Ended
                                                 March 31,               March 31,
                                        -------------------------  ------------------------
                                            2006         2005         2006         2005
                                        ------------  -----------  -----------  -----------
<S>                                     <C>           <C>          <C>          <C>
Revenues                                $         -            -            -            -
                                        ------------  -----------  -----------  -----------

General and administrative expense         (250,519)    (213,036)    (691,546)    (604,296)
                                        ------------  -----------  -----------  -----------

Loss from operations                       (250,519)    (213,036)    (691,546)    (604,296)
                                        ------------  -----------  -----------  -----------

Other income (expense):
  Other income                                    -           30       28,585       10,538
  Interest income, related party             31,895        5,720       40,245       11,907
  Equity losses of affiliates (Note 3)      (40,242)     (64,918)    (429,896)    (114,215)
  Loss on revaluation of derivative
    warrant liability (Note 5)              (70,137)           -      (74,295)           -
  Interest expense                                -            -     (235,131)           -
  Interest expense, related party                 -            -         (219)           -
                                        ------------  -----------  -----------  -----------
                                           (78,484)      (59,168)    (670,711)     (91,770)
                                        ------------  -----------  -----------  -----------

Net loss                                   (329,003)    (272,204)  (1,362,257)    (696,066)
                                        ------------  -----------  -----------  -----------

Beneficial conversion feature (Note 1)   (1,500,000)           -   (1,500,000)           -
                                        ------------  -----------  -----------  -----------

Net loss applicable to common
  shareholders                          $(1,829,003)    (272,204)  (2,862,257)    (696,066)
                                        ============  ===========  ===========  ===========

Net loss per share, basic and diluted
  (Note 1)                              $     (0.11)       (0.06)       (0.29)       (0.15)
                                        ============  ===========  ===========  ===========

Weighted average number of common
  shares outstanding (Note 1)            16,972,602    4,562,952    9,818,450    4,537,697
                                        ============  ===========  ===========  ===========

     See notes to condensed consolidated financial statements.
</TABLE>


                                     F-3
<PAGE>
<TABLE>
<CAPTION>
                             VYTA CORP AND SUBSIDIARIES
                  (FORMERLY KNOWN AS NANOPIERCE TECHNOLOGIES, INC.)
               Condensed Consolidated Statements of Comprehensive Loss
                                     (Unaudited)

                                   Three Months Ended          Nine Months Ended
                                        March 31,                 March 31,
                              --------------------------  --------------------------
                                   2006          2005         2006           2005
                              ------------  ------------  ------------  ------------
<S>                           <C>           <C>           <C>           <C>
Net loss                      $  (329,003)     (272,204)   (1,362,257)     (696,066)

Change in unrealized loss on
  securities                         (371)          (72)         (385)         (367)
                              ------------  ------------  ------------  ------------

Comprehensive loss            $  (329,374)     (272,276)   (1,362,642)     (696,433)
                              ============  ============  ============  ============

     See notes to condensed consolidated financial statements.
</TABLE>


                                     F-4
<PAGE>
<TABLE>
<CAPTION>
                                                    VYTA CORP AND SUBSIDIARIES
                                         (FORMERLY KNOWN AS NANOPIERCE TECHNOLOGIES, INC.)
                                Condensed Consolidated Statement of Changes in Shareholders' Equity
                                                 Nine Months Ended March 31, 2006
                                                            (Unaudited)

                              Preferred stock         Common stock      Additional  Accumulated other                    Total
                           ----------------------  -------------------   paid-in      comprehensive    Accumulated   shareholders'
                             Shares      Amount      Shares    Amount    capital         income          deficit        equity
                           ---------  -----------  ----------  -------  ----------  ----------------  -------------  -------------
<S>                        <C>        <C>          <C>         <C>      <C>         <C>               <C>            <C>
Balances, July 1, 2005
  (Note 1)                        -            -    4,663,045  $   466  24,059,377           122,843   (23,629,319)       553,367

Common stock issued upon
  exercise of warrants,
  net of offering costs
  (Notes 6 and 7)                 -            -    1,535,000      154     734,846                 -             -        735,000

Forgiveness of offering
  cost liability
  (Note 6)                        -            -            -        -     800,000                 -             -        800,000

Common stock issued upon
  issuance of notes
  payable
  (Notes 4 and 7)                 -            -      455,000       46     117,840                 -             -        117,886

Common stock and
  warrants issued for
  cash (Notes 5 and 7)            -            -      790,467       79     453,067                 -             -        453,146

Common stock issued as
  payment of commission           -            -       50,000        5      89,995                 -             -         90,000

Series A preferred stock
  issued for cash and
  note receivable           200,000    1,500,000            -        -           -                 -             -      1,500,000

Common stock issued upon
  conversion of Series A
  preferred stock          (200,000)  (1,500,000)  15,000,000    1,500   1,498,500                 -             -              -

Reclassification of
  derivative warrant
  liability to equity
  (Note 5)                        -            -            -        -     253,521                 -             -        253,521

Forgiveness of accrued
  payroll owed to
  officer /shareholder            -                         -        -       8,750                 -             -          8,750

Net loss                          -            -            -        -           -                 -    (1,362,257)    (1,362,257)
</TABLE>

                                   (continued)


                                     F-5
<PAGE>
<TABLE>
<CAPTION>
                                                 VYTA CORP AND SUBSIDIARIES
                                      (FORMERLY KNOWN AS NANOPIERCE TECHNOLOGIES, INC.)
                             Condensed Consolidated Statement of Changes in Shareholders' Equity
                                              Nine Months Ended March 31, 2006
                                                         (Unaudited)
                                                         (Continued)

                          Preferred stock       Common stock      Additional  Accumulated other                     Total
                          ----------------  --------------------   paid-in      comprehensive     Accumulated   shareholders'
                          Shares    Amount    Shares     Amount    capital          income          deficit        equity
                          -------  -------  ----------  --------  ----------  -----------------  -------------  ------------
<S>                       <C>      <C>      <C>         <C>       <C>         <C>                <C>            <C>
Other comprehensive
  loss:
    Change in unrealized
      gain on securities        -        -           -         -           -                385             -            385
                          -------  -------  ----------  --------  ----------  -----------------  -------------  ------------
Balances,
  March 31, 2006                -        -  22,493,512  $  2,250  28,015,896            123,228   (24,991,576)     3,149,798
                          =======  =======  ==========  ========  ==========  =================  =============  ============

See notes to condensed consolidated financial statements.
</TABLE>


                                     F-6
<PAGE>
<TABLE>
<CAPTION>
                                VYTA CORP AND SUBSIDIARIES
                    (FORMERLY KNOWN AS NANOPIERCE TECHNOLOGIES, INC.)
                     Condensed Consolidated Statements of Cash Flows
                                       (Unaudited)

                                                                   Nine Months Ended
                                                                       March 31,
                                                              ---------------------------
                                                                  2006           2005
                                                              -------------  ------------
<S>                                                           <C>            <C>
Cash flows from operating activities:
 Net loss                                                     $ (1,362,257)     (696,066)
                                                              -------------  ------------
 Adjustments to reconcile net loss to net cash used
  in operating activities:
  Amortization expense                                              67,561             -
  Depreciation expense                                               4,281         5,441
  Equity losses of affiliates                                      429,896       114,215
  Amortization of discounts on notes payable                       213,760             -
  Provision for losses on note receivable                                -        35,000
  Loss on revaluation of derivative warrant
    liability (Note 5)                                              74,295             -
  Changes in operating assets and liabilities:
  Increase in interest and other receivables                       (11,607)       (3,359)
  (Increase) decrease in prepaid expenses                          (15,623)       40,968
  (Decrease) increase in accounts payable and accrued
    liabilities                                                    (52,473)       50,607
                                                              -------------  ------------
 Total adjustments                                                 710,090       242,872
                                                              -------------  ------------

    Net cash used in operating activities                         (652,167)     (453,194)
                                                              -------------  ------------

Cash flows from investing activities:
  Increase in notes receivable                                    (875,000)     (349,000)
  Increase in advances receivable                                        -      (225,000)
  Payment on note receivable                                       275,442             -
  Investment in joint venture (Note 3)                            (500,000)            -
                                                              -------------  ------------
    Net cash used in investing activities                       (1,099,558)     (574,000)
                                                              -------------  ------------

Cash flows from financing activities:
  Exercise of warrants and common stock and warrants issued
    for cash                                                     2,167,372       112,801
  Proceeds from preferred stock purchase (Note 6)                  494,922             -
  Payment of notes payable                                        (960,663)      (61,400)
  Proceeds from issuance of notes payable and common stock         150,000             -
                                                              -------------  ------------
    Net cash provided by financing activities                    1,851,631        51,401
                                                              -------------  ------------

Net increase (decrease) in cash and cash equivalents                99,906      (975,793)

Cash and cash equivalents, beginning                                25,835     1,018,408
                                                              -------------  ------------

Cash and cash equivalents, ending                             $    125,741        42,615
                                                              =============  ============
</TABLE>

                                   (Continued)


                                     F-7
<PAGE>
<TABLE>
<CAPTION>
                               VYTA CORP AND SUBSIDIARIES
                   (FORMERLY KNOWN AS NANOPIERCE TECHNOLOGIES, INC.)
                    Condensed Consolidated Statements of Cash Flows
                                       (Unaudited)
                                       Continued
                                                                   Nine Months Ended
                                                                       March 31,
                                                               ------------------------
                                                                   2006         2005
                                                               ------------  ----------
<S>                                                            <C>           <C>
Supplemental disclosure of cash flow information:
  Cash paid for interest                                       $    23,569            -
                                                               ============  ==========

Supplemental disclosure of non-cash investing and financing
  activities:
    Issuance of Series A Preferred Stock in exchange for note
      receivable                                               $ 1,100,000            -
                                                               ============  ==========
    Beneficial conversion feature                              $ 1,500,000            -
                                                               ============  ==========
    Reclassification of derivative warrant liability to
      equity                                                   $   253,521            -
                                                               ============  ==========
    Issuance of common stock in connection with notes payable  $   117,886            -
                                                               ============  ==========
    Issuance of common stock in exchange for accrued
      commissions                                              $    90,000            -
                                                               ============  ==========
    Advances receivable applied to equity investment           $   405,000            -
                                                               ============  ==========
    Equity investment acquired in exchange for note payable    $   595,000            -
                                                               ============  ==========
    Liability recorded for offering costs of common stock
      issuance                                                 $   800,000            -
                                                               ============  ==========
    Forgiveness of offering costs owed in connection with
      common stock issuance                                    $  (800,000)           -
                                                               ============  ==========
    Forgiveness of accrued payroll owed to
      officer/shareholder                                      $     8,750            -
                                                               ============  ==========

     See notes to condensed consolidated financial statements.
</TABLE>


                                     F-8
<PAGE>
                           VYTA CORP AND SUBSIDIARIES
                (Formerly Known as NanoPierce Technologies, Inc.)
            Notes to the Condensed Consolidated Financial Statements
                    Nine Months Ended March 31, 2006 and 2005
                                   (Unaudited)

1.   BUSINESS,  ORGANIZATION  AND  SUMMARY  OF  SIGNIFICANT ACCOUNTING POLICIES:

PRESENTATION OF INTERIM INFORMATION:

The  accompanying  condensed  consolidated  financial  statements  include  the
accounts  of  NanoPierce  Technologies,  Inc.,  a  Nevada  corporation, which on
January  31,  2006 changed its name to Vyta Corp (the Company), its wholly-owned
subsidiaries,  NanoPierce Connection Systems, Inc., a Nevada corporation (NCOS),
and  ExypnoTech,  LLC  (ET LLC), a Colorado limited liability company, which was
formed  in  June  2004.  All  significant intercompany accounts and transactions
have  been  eliminated  in  consolidation.

On  January 19, 2006, the Company's Board of Directors (the "Board") approved an
amendment  to the Company's Articles of Incorporation to effect a one-for-twenty
reverse  stock  split  effective  January  31,  2006.  All references to shares,
options,  and  warrants in the three and nine months ended March 31, 2005 and in
prior  periods,  have  been  adjusted to reflect the post-reverse split amounts.
The  Company's  common  stock  now trades on the Over-the-Counter Bulletin Board
under  the  trading  symbol  "VYTC".

As  a  result of the reverse split, the Company's authorized capital was reduced
from 200,000,000 shares to 10,000,000 shares.  As part of the reverse split, the
Company  amended  and  restated  its  Articles  of Incorporation to increase the
authorized  capital  of  the  Company  to  200,000,000  shares.

In  the  opinion  of  the  management of the Company, the accompanying unaudited
condensed  consolidated  financial  statements include all material adjustments,
including  all normal and recurring adjustments, considered necessary to present
fairly  the  financial  position  and  operating  results of the Company for the
periods  presented.  The  financial  statements  and  notes  are  presented  as
permitted by Form 10-QSB, and do not contain certain information included in the
Company's  Annual Report on Form 10-KSB for the fiscal year ended June 30, 2005.
It  is the Company's opinion that when the interim financial statements are read
in  conjunction  with  the  June  30,  2005  Annual  Report  on Form 10-KSB, the
disclosures  are  adequate  to  make  the  information presented not misleading.
Interim results are not necessarily indicative of results for a full year or any
future  period.


                                     F-9
<PAGE>
                           VYTA CORP AND SUBSIDIARIES
                (Formerly Known as NanoPierce Technologies, Inc.)
            Notes to the Condensed Consolidated Financial Statements
                    Nine Months Ended March 31, 2006 and 2005
                                   (Unaudited)

MANAGEMENT'S  PLANS:

In the Company's Annual Report on Form 10-KSB for the fiscal year ended June 30,
2005,  the  Report of the Independent Registered Public Accounting Firm includes
an  explanatory  paragraph  that describes substantial doubt about the Company's
ability  to  continue  as  a  going  concern.  The  Company's  interim financial
statements for the nine and three months ended March 31, 2006 have been prepared
on  a  going concern basis, which contemplates the realization of assets and the
settlement of liabilities and commitments in the normal course of business.  The
Company  reported  a  net loss of $1,362,257 and a net loss applicable to common
shareholders  of  $2,862,257  for  the  nine months ended March 31, 2006, and an
accumulated  deficit  of  $24,991,576 as of March 31, 2006.  The Company has not
recognized  any  revenues  from  its  business  operations.

These factors raise substantial doubt about the Company's ability to continue as
a  going  concern.  The  financial  statements  do  not  contain any adjustments
relating  to  the recoverability and classification of assets or the amounts and
classification  of  liabilities  that  might  be necessary should the Company be
unable  to  continue  as  a  going  concern.

Currently,  the  Company  does  not  have  a  revolving  loan agreement with any
financial institution, nor can the Company provide any assurance it will be able
to  enter  into  any  such  agreement  in  the future, or be able to raise funds
through  a  further  issuance  of  debt  or  equity  in  the  Company.

RECENT  EVENTS:

In August 2005, the Company was able to raise $1,535,000 through the exercise of
1,535,000  warrants with an exercise price of $1.00 per share.  The Company used
$1,095,000 of the funds to complete its purchase of a 50% equity investment in a
joint  venture,  BioAgra,  LLC,  a  Georgia  limited  liability  company
("BioAgra")(Note  3),  and  the  Company  used  approximately  $366,000  to  pay
outstanding  notes  payable  (Note 4). The remaining $75,000 was used to support
operations.

In  September  2005,  the Company executed a subscription agreement with Arizcan
Properties,  Ltd.  ("Arizcan")  to sell shares of the Company's preferred stock.
The  sole  director  of  Arizcan  is  related  to  a board member and officer of
Intercell  International  Corporation  ("Intercell"), in which the Company has a
nominal  interest.  Ms.  Kampmann,  the  Company's  Chief Financial Officer, has
served  as  the  Chief Financial Officer of Intercell since October 2003 and Mr.
Metzinger,  the Company's Chief Executive Officer, served as the Chief Executive
Officer  of  Intercell  from  September  2004  until  March  2005.


                                      F-10
<PAGE>
                           VYTA CORP AND SUBSIDIARIES
                (Formerly Known as NanoPierce Technologies, Inc.)
            Notes to the Condensed Consolidated Financial Statements
                    Nine Months Ended March 31, 2006 and 2005
                                   (Unaudited)

The subscription agreement provided for the sale of 200,000 shares of Class A 8%
cumulative  and  participating  preferred shares for $7.50 per share. In January
2006,  Arizcan  purchased  200,000  shares of the Company's Series A Convertible
Preferred  Stock  ("Preferred  Stock")  for  $400,000  cash  and  an  unsecured
promissory  note  for  $1,100,000.  The promissory note bears interest at 8% per
annum  and  is  due  in  January  2007.  In February 2006, Arizcan converted the
200,000  shares  of  preferred  stock  into  15,000,000  shares of the Company's
restricted  common stock. Upon the conversion, Arizcan held approximately 67% of
the  issued  and outstanding common stock of the Company. The conversion feature
was  deemed  beneficial  and  accordingly  resulted  in  a beneficial conversion
feature  of $1,500,000. The intrinsic value of the beneficial conversion feature
is  limited  to  the  total  amount of the proceeds received. As a result of the
beneficial  conversion  feature,  net loss applicable to common shareholders was
increased  by  $1,500,000 during the three and nine months ended March 31, 2006.
Through  May 2006, Arizcan paid the Company cash of $1,100,000 to repay the note
in  full. Since the note was paid in full prior to the issuance of the March 31,
2006 financial statements, the note receivable has been presented as an asset at
March  31,  2006.

DEFERRED CONSULTING COSTS:

In  June  2005,  the  Company  entered  into  a twelve-month consulting services
agreement  with  a third party, in which this party agreed to provide public and
investor  relation  services  and general business services for the twelve-month
term of the agreement.  Compensation consisted of 50,000 shares of the Company's
restricted  common  stock with a market value of approximately $90,000 (based on
the  closing  market  price  of $1.80 per share at the date of the transaction).
The  deferred  cost  is  being  amortized  on  a  straight-line  basis  over the
twelve-month  period  from  the  date  of the agreement.  During the nine months
ended  March  31,  2006,  $67,561  was  expensed.

LOSS PER SHARE:

Statement  of Financial Accounting Standards (SFAS) No. 128, Earnings Per Share,
requires dual presentation of basic and diluted earnings or loss per share (EPS)
with  a  reconciliation  of  the  basic  EPS  computation  to  the numerator and
denominator  of  the  diluted  EPS  computation.  Basic  EPS  excludes dilution.
Diluted  EPS  reflects  the potential dilution that could occur if securities or
other  contracts  to  issue common stock were exercised or converted into common
stock  or  resulted  in  the  issuance  of  common stock that then shared in the
earnings of the entity.  Loss per share of common stock is computed based on the
weighted  average  number of common shares outstanding during the period.  Stock
options and warrants are not considered in the calculation, as the impact of the
potential common shares (6,029,468 shares at March 31, 2006 and 3,809,094 shares
at March 31, 2005) would be to decrease loss per share.  Therefore, diluted loss
per  share  is  equivalent  to  basic  loss  per  share.


                                      F-11
<PAGE>
                           VYTA CORP AND SUBSIDIARIES
                (Formerly Known as NanoPierce Technologies, Inc.)
            Notes to the Condensed Consolidated Financial Statements
                    Nine Months Ended March 31, 2006 and 2005
                                   (Unaudited)

ACCOUNTING  FOR OBLIGATIONS AND INSTRUMENTS POTENTIALLY SETTLED IN THE COMPANY'S
COMMON  STOCK:

The  Company  accounts for obligations and instruments potentially to be settled
in  the  Company's stock in accordance with EITF Issue No. 00-19, ACCOUNTING FOR
DERIVATIVE  FINANCIAL  INSTRUMENTS  INDEXED  TO,  AND  POTENTIALLY  SETTLED IN A
COMPANY'S  OWN  STOCK.  This  issue  addresses  the  initial  balance  sheet
classification and measurement of contracts that are indexed to, and potentially
settled  in,  the  Company's  stock.

Under  EITF  00-19,  contracts  are  initially classified as equity or as either
assets  or  liabilities, depending on the situation. All contracts are initially
measured  at fair value and subsequently accounted for based on the then current
classification.  Contracts  initially  classified  as  equity  do  not recognize
subsequent  changes  in  fair  value  as  long  as  the contracts continue to be
classified  as  equity.  For  contracts classified as assets or liabilities, the
Company reports changes in fair value in earnings and discloses these changes in
the financial statements as long as the contracts remain classified as assets or
liabilities.  If  contracts  classified  as assets or liabilities are ultimately
settled  in  shares,  any previously reported gains or losses on those contracts
continue  to  be  included  in  earnings.  The  classification  of a contract is
reassessed  at  each  balance  sheet  date.

STOCK-BASED COMPENSATION:

SFAS  No.  123,  Accounting  for  Stock  Based Compensation, allows companies to
choose  whether to account for employee stock-based compensation on a fair value
method,  or  to  continue  accounting  for such compensation under the intrinsic
value  method  prescribed  in  Accounting  Principles  Board  Opinion  No.  25,
Accounting  for  Stock  Issued to Employees (APB 25).  The Company has chosen to
continue  to  account  for  employee  stock-based  compensation  using  APB  25.

No options were granted to employees during the nine months ended March 31, 2006
or  2005.

RECENTLY  ISSUED  ACCOUNTING  STANDARD:

In  December  2004,  the Financial Accounting Standards Board (FASB) issued SFAS
No.  123(R), Share-Based Payment, which addresses the accounting for share-based
payment  transactions.  SFAS  No.  123(R)  eliminates the ability to account for
share-based  compensation  transactions  using  APB  25,  and generally requires
instead  that  such transactions be accounted and recognized in the statement of
operations based on their fair value.  SFAS No. 123(R) will be effective for the
Company  beginning  on  July  1,  2006.  Management  is currently evaluating the
provisions  of this standard.  Depending upon the number of and terms of options
that may be granted in future periods, the implementation of this standard could
have  a  significant  impact  on the Company's financial position and results of
operations  in  future  periods.


                                      F-12
<PAGE>
                           VYTA CORP AND SUBSIDIARIES
                (Formerly Known as NanoPierce Technologies, Inc.)
            Notes to the Condensed Consolidated Financial Statements
                    Nine Months Ended March 31, 2006 and 2005
                                   (Unaudited)

2.   NOTES AND  ADVANCES  RECEIVABLE:

In  January  2006,  the Company sold 200,000 shares of Class A 8% cumulative and
participating  preferred  shares  for  $400,000 cash and an unsecured promissory
note  for  $1,100,000 to Arizcan.  The promissory note has a due date of January
17, 2007 and a 8% annual interest rate.  During the three months ended March 31,
2006,  the  Company received payments totaling $110,000, which included interest
of  $11,729.  On  March  31,  2006,  the  note  had  an  outstanding  balance of
$1,005,298,  of which $220 was accrued interest.  During April and May 2006, the
Company  received  payments  totaling  $1,010,097,  of  which $5,019 was accrued
interest.  The  note  was  paid  in  full  in  May  2006.

During  the  nine  months  ended  March 31, 2006, the Company loaned $875,000 to
BioAgra (Note 3).  In exchange for the loans, the Company received secured, 7.5%
promissory  notes,  of  which $700,000 are due on June 30, 2006 and $175,000 are
due  on  August  31,  2006.  The  funds  were  loaned  to  facilitate  BioAgra's
completion  of  its  first  production  line  and  the purchase of inventory for
production.  The  promissory  notes  are  collateralized  by  all  equipment,
furnishings,  present  and  future  accounts, collateral securing such accounts,
tangible  and  intangible  personal  property  and  any proceeds from any of the
foregoing located on BioAgra's premises.  Additionally, the promissory notes are
to  be  paid in full prior to any disbursements being made to the members of the
joint  venture.  During April 2006, the Company loaned an additional $600,000 to
BioAgra  with  the  same terms as the original promissory notes, which is due on
October  31,  2006.  During  May  2006, the Company loaned BioAgra an additional
$186,570,  with the same terms as the original promissory notes, which is due on
October  31,  2007.

In  November  2004, the Company loaned $314,000 to Arizcan.  In exchange for the
loan,  the  Company  received an unsecured, 7% promissory note, which was due on
October  31, 2005.  The funds were loaned to facilitate Arizcan's purchase of an
option  from  certain of the Company's warrant holders, to initiate the exercise
of  certain  existing warrants to purchase up to 785,000 shares of the Company's
common stock (Note 6).  In June 2005, the Company received a payment of $50,000,
which  included  interest  of $11,442.  In December 2005, the Company received a
payment  of  $100,000, which included interest of $10,881. In February 2006, the
Company  received payments totaling $188,718, which included interest of $2,395.
The  note  was  paid  in  full  at  that  time.

In  October  and November 2004, the Company advanced a total of $150,000 to Xact
Resources  International,  Inc.  ("Xact  Resources"),  which  was applied to the
purchase  of  a  50%  equity  interest  in  BioAgra on August 15, 2005 (Note 3).

In  December  2004,  the  Company  loaned  $35,000 to Intercell in return for an
unsecured, 7% promissory note, due in December 2005.  The loan was made in order
to  assist  Intercell in its efforts to support operations.    During the fiscal
year  ended June 30, 2005, the Company deemed the debt uncollectible and created
an  allowance  for  the  receivable  of  $35,000.


                                      F-13
<PAGE>
                           VYTA CORP AND SUBSIDIARIES
                (Formerly Known as NanoPierce Technologies, Inc.)
            Notes to the Condensed Consolidated Financial Statements
                    Nine Months Ended March 31, 2006 and 2005
                                   (Unaudited)

3.   INVESTMENTS  IN  AFFILIATES:

INVESTMENT IN EXYPNOTECH, GMBH:

In  December  2003,  TagStar  Sytems,  Gmbh,  a  German  entity formed by former
employees  of  ExypnoTech,  Gmbh  ("EPT"),  purchased  a  controlling 51% equity
interest  in  EPT  in  exchange  for $98,000, of which $62,787 has been received
through  March  31,  2006.  The Company accounts for its investment in EPT under
the  equity  method  of  accounting.  Under the equity method of accounting, the
carrying  amount of the Company's investment in EPT ($201,954 at March 31, 2006)
is  adjusted  to  recognize  the  Company's  proportionate share of EPT's income
(loss)  each  period.

Unaudited  financial  information  of EPT as of March 31, 2006, and for the nine
and  three-month  periods  ended  March  31,  2006  and  2005  are  as  follows:

<TABLE>
<CAPTION>
                                                   March 31,
                                                     2006
                                                  ----------
<S>                                               <C>
          Assets:
              Current assets(1)                   $  648,944
              Equipment                              111,950
                                                  ----------

            Total assets                          $  760,894
                                                  ==========

          Liabilities and members' equity:
              Current liabilities                 $  496,649
              Members' equity                        264,245
                                                  ----------

          Total liabilities and members' equity   $  760,894
                                                  ==========

          (1)  Current  assets  include  receivables  of  $222,246  due from the
               51%  owner  of  EPT.
</TABLE>

<TABLE>
<CAPTION>
                   Three Months Ended            Nine Months Ended
                        March 31,                    March 31,
                  2006            2005          2006          2005
             --------------  ------------  -------------  ------------
<S>          <C>             <C>           <C>            <C>
Revenues(1)  $     821,429       171,716      1,866,625        34,885
Expenses(2)       (638,675)     (147,112)    (1,780,275)     (246,556)
             --------------  ------------  -------------  ------------
Net income
  (loss)     $     182,754        24,604         86,350      (211,671)
             ==============  ============  =============  ============

     (1)  Revenues  include  $1,550,832  and  $9,562  of  sales to the 51% owner
          of EPT for the nine months ended March 31, 2006 and 2005, respectively
          ($505,710  and  $9,562  for  the three months ended March 31, 2006 and
          2005,  respectively).
     (2)  Expenses  include  $83,525  and  $19,070,  respectively  of  charges
          paid  to the 51% owner of EPT for the nine months ended March 31, 2006
          and 2005, respectively ($37,854 and $19,070 for the three months ended
          March  31,  2006  and  2005,  respectively).
</TABLE>


                                      F-14
<PAGE>
                           VYTA CORP AND SUBSIDIARIES
                (Formerly Known as NanoPierce Technologies, Inc.)
            Notes to the Condensed Consolidated Financial Statements
                    Nine Months Ended March 31, 2006 and 2005
                                   (Unaudited)

EPT  operations  are  located  in  Germany.  EPT  transactions  are conducted in
currencies  other  than  the  U.S.  dollar,  (the  currency  into  which  the
subsidiaries'  historical  financial  statements have been translated) primarily
the  Euro.  As  a result, the Company is exposed to adverse movements in foreign
currency  exchange  rates.

In  addition,  the Company is subject to risks including adverse developments in
the  foreign  political  and  economic  environments,  trade  barriers, managing
foreign  operations  and  potentially adverse tax consequences.  There can be no
assurance  that  any of these factors will not have a material adverse effect on
the  Company's  financial  condition  or  results  of  operations in the future.

INVESTMENT IN BIOAGRA:

On  August  15,  2005,  the  Company  entered  into  a  joint  venture with Xact
Resources,  a  privately  held  company.  The  Company  purchased  a  50% equity
interest  in  the  joint  venture, BioAgra, for $905,000 in cash (which includes
$405,000  previously  advanced to Xact Resources as of June 30, 2005) and a note
payable  of  $595,000, which was paid in full on September 15, 2005.  BioAgra is
to  manufacture  and  sell  a  beta  glucan  product,  YBG-2000  also  known  as
AgraStimTM,  to  be  used  as  a  replacement  for  hormone  growth steroids and
antibiotics  in  products  such  as  poultry  feed.

BioAgra (a development stage company) has completed construction of a production
line.  BioAgra  began  producing  and shipping product during the quarter ending
June  30,  2006.

The  terms of the joint venture provide for the Company to share in 50% of joint
venture  net  income,  if any, or net losses.  The Company is accounting for its
investment  in  BioAgra  as an equity method investment.  At March 31, 2006, the
Company's  investment  in  BioAgra  is  $1,027,792.


                                      F-15
<PAGE>
                           VYTA CORP AND SUBSIDIARIES
                (Formerly Known as NanoPierce Technologies, Inc.)
            Notes to the Condensed Consolidated Financial Statements
                    Nine Months Ended March 31, 2006 and 2005
                                   (Unaudited)

Unaudited  financial  information  of  BioAgra  as of March 31, 2006 and for the
three  month  period  ended  March  31, 2006 and the period from August 15, 2005
through  March  31,  2006,  is  as  follows:

<TABLE>
<CAPTION>
<S>                                                        <C>
                                                            March 31,
                                                              2006
                                                           ----------
          Assets:
              Current assets                               $    5,828
              Equipment, net                                1,791,087
              Land and building under capital lease, net    1,107,531
                                                           ----------
            Total assets                                   $2,904,446
                                                           ==========

          Liabilities and members' equity:
              Current liabilities(1)                       $1,345,617
              Obligation under capital lease(2)             1,003,246
                                                           ----------

            Total liabilities                               2,348,863

              Members' equity                                 555,583
                                                           ----------

          Total liabilities and members' equity            $2,904,446
                                                           ==========

          (1)  Includes  $875,000  owed  to  the  Company.  (2)  BioAgra  leases
               land  and  a building under a ten-year lease expiring in February
               2015,  which  requires  a  monthly  lease  payment  of  $12,000.
</TABLE>

<TABLE>
<CAPTION>
                                      August 15, 2005
                Three Months Ended        through
                  March 31, 2006      March 31, 2006
               --------------------  -----------------
<S>            <C>                   <C>
     Revenues  $                 -   $              -
     Expenses             (259,584)          (944,416)
               --------------------  -----------------
     Net loss  $          (259,584)  $       (944,416)
               ====================  =================
</TABLE>

INVESTMENT  IN  SCIMAXX  SOLUTIONS,  LLC:

On  September  15,  2003, the Company entered into an agreement to receive a 50%
interest  in a joint venture agreement with Scimaxx, LLC.  The name of the joint
venture  was  Scimaxx  Solutions,  LLC  (Scimaxx Solutions).  The purpose of the
joint  venture  was to provide the electronics industry with technical solutions
to  manufacturing  problems  based  on  the  need  for  electrical connectivity.

At March 31, 2005, Scimaxx Solutions had total assets of $70,531 of which $76
were current assets and $70,455 were equipment, total liabilities of $73,295 and
members' deficit of $2,764.


                                      F-16
<PAGE>
                           VYTA CORP AND SUBSIDIARIES
                (Formerly Known as NanoPierce Technologies, Inc.)
            Notes to the Condensed Consolidated Financial Statements
                    Nine Months Ended March 31, 2006 and 2005
                                   (Unaudited)

For  the  three and nine months ended March 31, 2005, Scimaxx Solutions recorded
revenues  of  $0  and $5,773, respectively, and expenses of $27,461 and $80,781,
respectively,  resulting  in  a  net  loss of $27,461 and $75,008, respectively.
Scimaxx  Solutions  ceased  operations  in  April  2005.

4.   NOTES AND  ADVANCES  PAYABLE:

RELATED PARTIES:

In  June  2005, an officer/director of the Company loaned $41,000 to the Company
in  exchange  for  an  unsecured, 5% note payable due in December 2005.  In June
2005,  the  Company paid $337 plus accrued interest of $17.  In August 2005, the
Company  paid  the  remaining  $40,663  plus  accrued  interest  of  $298.

OTHER:

In  June  2005, an unrelated party loaned the Company $25,000 in exchange for an
unsecured,  8%  promissory  note  due  in December 2005 and 75,000 shares of the
Company's  restricted  common stock, which were issued in July 2005.  The common
stock had a market value of $150,000 (based on the closing market price of $2.00
per share on the date of the transaction). The relative fair value of the common
stock  ($21,428)  was accounted for as a discount against the face amount of the
note.  The effective interest rate on this note was 85%.  On August 8, 2005, the
Company paid the $25,000, plus accrued interest of $208.  Through that date, the
discount  of  $21,428  was  fully  amortized  to  interest  expense.

In  June  2005, an unrelated third party loaned the Company $150,000 in exchange
for an unsecured, promissory note due in September 2005 with interest at 15% per
quarter  and  100,000  shares  of  the Company's restricted common stock (50,000
shares  were  issued in June 2005 and the remaining 50,000 shares were issued in
July  2005).  At  the  date  of issuance, the common stock had a market value of
$180,000  (based  on  the closing market price of $1.80 per share on the date of
the  transaction).  The  relative  fair  value of the common stock ($81,718) was
accounted  for  as  a discount applied against the face amount of the note.  The
effective  interest  rate  on this note was 54%.  As of June 30, 2005, $7,272 of
the  discount had been amortized to interest expense.  On September 8, 2005, the
Company paid the $150,000, plus accrued interest of $22,500.  Through that date,
the  remaining  discount  of  $74,446  was  fully amortized to interest expense.


                                      F-17
<PAGE>
                           VYTA CORP AND SUBSIDIARIES
                (Formerly Known as NanoPierce Technologies, Inc.)
            Notes to the Condensed Consolidated Financial Statements
                    Nine Months Ended March 31, 2006 and 2005
                                   (Unaudited)

During  July  and  August 2005, six unrelated third parties loaned the Company a
total of $150,000 in exchange for unsecured, 8% promissory notes due in December
2005  and  a  total  of 330,000 shares of the Company's restricted common stock.
The  common  stock  had  a  total market value of $574,000 (based on the closing
market  prices  which  ranged  from $1.60 to $1.80 per share at the date of each
transaction).  The  relative  fair  value  of  the  common  stock ($117,886) was
accounted  for  as a discount applied against the face amount of the notes.  The
discount  was  amortized  over  the  terms of the promissory notes as additional
interest expense.  The effective interest rate on these notes is 85%.  On August
8,  2005, the Company paid the $150,000, plus accrued interest of $642.  Through
that  date,  the  discount  of $117,886 was fully amortized to interest expense.

5.   DERIVATIVE  WARRANT  LIABILITY:

During  November  and  December  2005,  the  Company  sold 500,625 shares of its
restricted  common  stock  for  $400,500.  In  connection  with  the sale of the
restricted  common  shares, the Company issued warrants exercisable into 500,625
shares of the Company's common stock.  The common stock had a total market value
of $714,125 (based on the closing market prices which ranged from $1.00 to $1.60
per  share  at  the  date  of  each transaction).  The warrants had an aggregate
estimated  fair value of $312,167 (using the Black-Scholes model).  The relative
fair  value  of  the  warrants  ($119,339)  was  accounted for as a liability in
accordance  with  EITF  00-19,  as  the Company's authorized and unissued shares
available  to  settle the warrants (after considering all other commitments that
may  require  the  issuance of stock during the maximum period the warrant could
remain  outstanding)  were  determined  to  be  insufficient.

During  December  2005, the Company sold 127,500 shares of its restricted common
stock  for $102,000.  These shares of common stock were not issued until January
2006.  In  connection with the sale of the restricted common shares, the Company
issued  warrants  exercisable  for 127,500 shares of the Company's common stock.
The  common  stock  had  a  total market value of $178,000 (based on the closing
market  prices  which  ranged  from $1.20 to $1.60 per share at the date of each
transaction).  The  warrants  had  an  aggregate estimated fair value of $76,657
(using  the  Black-Scholes  model).  The  relative  fair  value  of the warrants
($30,600) was accounted for as a liability in accordance with EITF 00-19, as the
Company's authorized and unissued shares available to settle the warrants (after
considering  all other commitments that may require the issuance of stock during
the  maximum  period the warrant could remain outstanding) were determined to be
insufficient.


                                      F-18
<PAGE>
                           VYTA CORP AND SUBSIDIARIES
                (Formerly Known as NanoPierce Technologies, Inc.)
            Notes to the Condensed Consolidated Financial Statements
                    Nine Months Ended March 31, 2006 and 2005
                                   (Unaudited)

During  January  2006,  the Company sold 118,592 shares of its restricted common
stock for $94,872.  In connection with the sale of the restricted common shares,
the  Company  issued  warrants  exercisable into 118,592 shares of the Company's
common  stock.  The  common  stock had a total market value $166,028 (based on a
closing  market  price of $1.40 per share at the date of each transaction).  The
warrants  had  an  aggregate  estimated  fair  value  of  $74,141  (using  the
Black-Scholes  model).  The  relative  fair  value of the warrants ($29,287) was
accounted  for  as  a  liability in accordance with EITF 00-19, as the Company's
authorized  and  unissued  shares  available  ot  settle  the  warrants  (after
considering  all other commitments that may require the issuance of stock during
the  maximum  period the warrant could remain outstanding) were determined to be
insufficient.

At  December  31, 2005, the Company's authorized and unissued common shares were
insufficient to settle these warrant contracts.  As a result, the value of these
warrants  was  classified  as  a  liability.  As  a result of the one-for-twenty
reverse  stock  split  in  February  2006 and the increase in authorized shares,
there  are  now sufficient authorized and unissued common shares to settle these
contracts.  Accordingly, the fair value of the warrants at the effective date of
the  stock  split  was  reclassified  to additional paid-in capital.  During the
three  and  nine  months  ended  March  31,  2006 the Company recorded a loss of
$70,137  and  $74,295, respectively, on these contracts.  The appropriateness of
the  classification of these contracts is reassessed at each balance sheet date.

6.   OTHER LIABILITIES

The  Company  had  recorded an $800,000 payable to Arizcan, which represents the
costs  incurred in connection with a $1.5 million offering of equity securities.
In  March 2006, Arizcan terminated the agreement and forgave the payment of this
liability.  As  a  result,  in  March  2006,  the  Company  has reclassified the
liability  to  equity.

7.   SHAREHOLDERS'  EQUITY:

COMMON STOCK:

Current Year Transactions

In  connection with the issuance of a $150,000 promissory note in June 2005, the
Company agreed to issue 100,000 shares of its restricted common stock, valued at
$81,718, of which 50,000 shares were issued in June 2005, and 50,000 shares were
issued  in  July  2005.

In  connection  with the issuance of a $25,000 promissory note in June 2005, the
Company  agreed to issue 75,000 shares of its restricted common stock, valued at
$21,428,  which  were  issued  in  July  2005.


                                      F-19
<PAGE>
                           VYTA CORP AND SUBSIDIARIES
                (Formerly Known as NanoPierce Technologies, Inc.)
            Notes to the Condensed Consolidated Financial Statements
                    Nine Months Ended March 31, 2006 and 2005
                                   (Unaudited)

During July and August 2005, in connection with the issuance of promissory notes
totaling  $150,000,  the  Company issued 330,000 shares of its restricted common
stock,  valued  at  $117,886.

In  August  2005,  warrants  to  purchase  1,535,000 shares of common stock were
exercised  for  cash  proceeds of $1,535,000 in exchange for 1,535,000 shares of
common  stock.  The  exercise price of these warrants was lowered from $2.00 and
$3.00  per  share  to  $1.00  per  share  in  connection  with  the  exercise.

In  October  2005,  the  Company  issued  50,000 shares of its restricted common
stock,  valued  at  $90,000,  in satisfaction of a $90,000 liability incurred in
connection  with  the  Company's  financing  efforts.

During  October  2005, the Company issued 43,750 shares of its restricted common
stock  in  exchange  for  $35,000.  The shares had a purchase price of $0.80 per
share  (based  on a 50% discount from the closing market price, $1.60 per share,
on  the  date  of  each  transaction).

During  November  and  December  2005,  the Company issued 500,625 shares of its
restricted  common  stock  and  warrants  to  purchase  500,625  shares  of  its
restricted  common  stock  for $400,500.  The warrants have an exercise price of
$1.00  per  share  and  a  term  of  3  years.  The shares of common stock had a
purchase  price  of  $0.80  share.

During  December  2005, the Company sold 127,500 shares of its restricted common
stock  for  $102,000.  In  connection  with  the  sale  of the restricted common
shares, the Company issued three-year warrants to purchase 127,500 shares of the
Company's  common  stock  at  $1.00 per share.  The shares of common stock had a
purchase  price  of  $0.80  share.

In  January  2006,  the  Company  issued 118,592 shares of its restricted common
stock and warrants to purchase 118,592 shares of its restricted common stock for
$94,872.  The  warrants  have an exercise price of $1.00 per share and a term of
three  years.  The  shares  of  common  stock  had a purchase price of $0.80 per
share.

In  January  2006,  the Company sold 200,000 shares of Class A 8% cumulative and
participating  preferred  shares  for  $400,000 cash and an unsecured promissory
note for $1,100,000, which was repaid in cash in May 2006.  Each preferred share
was convertible into 75 shares of the Company's common stock.  In February 2006,
the 200,000 shares of the preferred shares were converted into 15,000,000 shares
of  the  Company's  restricted  common  stock.

Nine  Months  Ended  March  31,  2005

During the nine months ended March 31, 2005, the Company issued 1,200,000 shares
of  common  stock  upon  the  exercise  of  warrants.  The Company received cash
proceeds  of  $112,801  (net  of  $7,200  of  offering  costs).


                                      F-20
<PAGE>
                           VYTA CORP AND SUBSIDIARIES
                (Formerly Known as NanoPierce Technologies, Inc.)
            Notes to the Condensed Consolidated Financial Statements
                    Nine Months Ended March 31, 2006 and 2005
                                   (Unaudited)

WARRANTS:

During the nine months ended March 31, 2006, warrants to purchase 192,709 shares
of  common  stock  expired.

In  December  2005  warrants  to  purchase  238,667  shares of common stock were
canceled  by  their  holders.  The  warrants  were cancelled to reduce the total
dilutive  securities  below  the authorized share limit, to allow the Company to
enter  into  additional  equity  financing  in December 2005.  In return for the
cancellation  of such warrants, the Company agreed to issue warrants to purchase
3,500,000  common shares.  The warrants have an exercise price of $1.00 and have
a  term  of  3  years.  These  warrants  were  issued  in  February  2006.

In  February  2006,  the  Company  issued warrants to purchase 746,717 shares of
common  stock.  The  warrants were issued to full fill commitments made with the
sale  of  common  stock  from  November  2005 through January 2006, as discussed
above.  The  warrants  have an exercise price of $1.00 per share and a term of 3
years.

OPTIONS:

In  December  2005,  officers  and  a  director  of the Company agreed to cancel
options  under the Company's 1998 Compensatory Stock Option Plan exercisable for
31,250  shares  of  the  Company's  stock.

In January 2006, an officer and director of the Company agreed to cancel options
under  the  Company's 1998 Compensatory Stock Option Plan exercisable for 15,000
shares  of  the  Company's  stock.

The  officers  and  director did not receive any consideration in return for the
cancellations.

CAPITAL  TRANSACTION:

In  August 2005, an officer/shareholder of the Company forgave $8,750 of accrued
salary,  which  has been accounted for as a capital transaction and has resulted
in  an  increase  in  additional  paid  in  capital.


                                      F-21
<PAGE>
                           VYTA CORP AND SUBSIDIARIES
                (Formerly Known as NanoPierce Technologies, Inc.)
            Notes to the Condensed Consolidated Financial Statements
                    Nine Months Ended March 31, 2006 and 2005
                                   (Unaudited)

8.  COMMITMENTS AND CONTINGENCIES

LITIGATION:

Depository  Trust  Suit:

In  May  2004,  the Company filed suit against the Depository Trust and Clearing
Corporation  ("DTCC"),  the  Depository  Trust Company ("DTC"), and the National
Securities  Clearing  Corporation ("NSCC") in the Second Judicial District Court
of  the  County  of  Washoe,  State of Nevada.  The suit alleges multiple claims
under  the  Nevada  Revised  Statutes 90.570, 90.580, 90.660 and 598A.060 and on
other  legal  bases.  The  complaint alleges, among other things, that the DTCC,
DTC  and NSCC acted in concert to operate the "Stock Borrow Program," originally
created  to address short term delivery failures by sellers of securities in the
stock  market.  According  to the complaint, the DTCC, NSCC and DTC conspired to
maintain  significant  open  fail deliver positions of millions of shares of the
Company's  common  stock  for extended periods of time by using the Stock Borrow
Program  to  cover  these open and unsettled positions.  The Company was seeking
damages  in  the amount of $25,000,000 and treble damages.  Responsive pleadings
have  been  filed  by  the  defendants.  On  April 27, 2005, the court granted a
motion  to  dismiss the lawsuit. The Company has filed an appeal to overturn the
motion  to  dismiss  the  lawsuit.

Financing  Agreement  Suit:

In  connection  with  a  financing  obtained  in October 2000, the Company filed
various actions in the United States District Court for the District of Colorado
against,  among others, Harvest Court, LLC, Southridge Capital Investments, LLC,
Daniel  Pickett,  Patricia  Singer and Thomson Kernaghan, Ltd. for violations of
federal  and  state  securities laws, conspiracy, aiding and abetting and common
law  fraud  among  other  claims.  As a result of various procedural rulings, in
January  2002,  the  United  States  District Court for the District of Colorado
transferred  the  case  to  the  United  States  District Court for the Southern
District  of  New  York,  New  York City, New York.  In this litigation, Harvest
Court,  LLC  filed  counterclaims  against  the Company and certain officers and
former  board  members  of the Company, and a number of unrelated third parties.
The  counterclaims  allege violations of federal securities laws and other laws.
Harvest Court, LLC is seeking various forms of relief including compensatory and
punitive  damages.  Responsive  pleadings  have been filed and the litigation is
currently  in  the  discovery  stage.


                                      F-21
<PAGE>
                           VYTA CORP AND SUBSIDIARIES
                (Formerly Known as NanoPierce Technologies, Inc.)
            Notes to the Condensed Consolidated Financial Statements
                    Nine Months Ended March 31, 2006 and 2005
                                   (Unaudited)

In  May  2001,  Harvest Court, LLC filed suit against the Company in the Supreme
Court  of  the State of New York, County of New York.  The suit alleges that the
Company  breached  an  October 20, 2000 Stock Purchase Agreement, by not issuing
370,945 free trading shares of the Company's common stock in connection with the
reset  provisions  of  the  Purchase  Agreement due on the second reset date and
approximately  225,012  shares  due  in  connection  with  the third reset date.
Harvest  Court,  LLC  is  seeking  the delivery of such shares or damages in the
alternative.  In August 2001, the Supreme Court of the State of New York, County
of  New York issued a preliminary injunction ordering the Company to reserve and
not  transfer the shares allegedly due to Harvest Court, LLC.  In February 2006,
the  Supreme  Court  of  the  State  of  New  York, County of New York issued an
injunction  ordering  the  Company  to  reserve 3.7% of the Company's issued and
outstanding common stock (832,029 shares at February 13, 2006).  The Company has
set  aside  these  shares.  The  Company has filed counterclaims seeking various
forms  of  relief  against  Harvest  Court,  LLC.

The Company intends to vigorously prosecute this litigation and does not believe
the  outcome  of  this  litigation  will  have  a material adverse effect on the
financial  condition,  results  of  operations  or  liquidity  of  the  Company.
However, it is too early at this time to determine the ultimate outcome of these
matters.


                                      F-22
<PAGE>
ITEM 2. MANAGEMENT'S  DISCUSSION  AND  ANALYSIS

     Certain  statements  contained in this Form 10-QSB contain "forward-looking
statements"  within  the meaning of the Private Securities Litigation Reform Act
of  1995  and involve risks and uncertainties that could cause actual results to
differ  materially  from  the  results,  financial  or  otherwise,  or  other
expectations  described in such forward-looking statements.  Any forward-looking
statement  or statements speak only as of the date on which such statements were
made,  and  the  Company  undertakes no obligation to update any forward-looking
statement  to  reflect  events  or  circumstances  after  the date on which such
statements  are  made  or  reflect  the  occurrence  of  unanticipated  events.
Therefore, forward-looking statements should not be relied upon as prediction of
actual  future  results.

     Vyta Corp is referred to as "us", "we", or "Company" in this report.

     The independent registered public accounting firm's report on the Company's
consolidated financial statements as of June 30, 2005, and for each of the years
in  the  two-year  period  then  ended,  includes  a "going concern" explanatory
paragraph,  that  describes  substantial  doubt  about  the Company's ability to
continue  as  a  going  concern.  Management's  plans  in  regard to the factors
prompting  the  explanatory  paragraph are discussed below and also in Note 1 to
the  unaudited  quarterly  Financial  Statements.

RECENT  EVENTS

     On  January  19,  2006, the our board of directors approved an amendment to
our  Articles of Incorporation to change the name of the Company from NanoPierce
Technologies,  Inc.  to  Vyta  Corp.

     On  January  19,  2006  our board of directors approved an amendment to our
Articles  of  Incorporation  to  affect  a  one-for-twenty  reverse  stock split
effective  January  31, 2006. All references to shares, options, and warrants in
the  three  and nine months ended March 31, 2006 and in prior periods, have been
adjusted  to reflect the post-reverse split amounts. Our common stock now trades
on  the  Over-the-Counter  Bulletin  Board  under  the  trading  symbol  "VYTC".

     On  January  19,  2006, our board of directors approved an amendment to the
Articles  of  Incorporation  to  increase our authorized capital from 10,000,000
common  shares  to  200,000,000  common  shares.

RESULTS  OF  OPERATIONS

     We  had  no  revenues during the three and nine months ended March 31, 2006
and  2005.

     We  recognized $28,585 of other income, of which $28,250 represented a gain
on  the  extinguishment of liabilities. We recognized $40,245 in interest income
during  the nine months ended March 31, 2006 compared to $11,907 during the nine
months ended March 31, 2005 ($31,895 and $5,720 for the three months ended March
31,  2006  and  2005,  respectively).  The  increase  in interest income for the
periods  ended  March 31, 2006 is due to interest recorded on amounts owed to us
from  BioAgra  and  Arizcan  in  the  form  of  notes  receivable.


                                        1
<PAGE>
     Total  general  and  administrative  expenses  during the nine months ended
March  31,  2006  were  $691,546  compared to $604,296 for the nine months ended
March  31, 2005 ($250,519 and $213,036 for the three months ended March 31, 2006
and 2005, respectively).  The increase of $87,250 is primarily attributable to a
$70,010  increase  in  commission  fees,  a $40,679 increase in consulting fees,
increase  of  $29,176  in  legal  fees  offset  by  a $23,981 decrease in public
relations  expense.

     We  recognized interest expense of $235,350 for the nine months ended March
31, 2006 (no interest expense was recognized in the three months ended March 31,
2006).  No  interest expense was recorded during the three and nine months ended
March  31,  2005.  Of the $235,350 in interest expense, $219 represented related
party  interest.  The  remaining  $235,131  was  incurred in connection with the
issuance of promissory notes, which were discounted at the time of issuance. The
resulting  discounts  ($213,760)  were amortized over the term of the promissory
notes.  The  promissory notes were paid in full in August 2005, and at that time
the  discounts  were  fully  amortized.

     During  the  nine  months ended March 31, 2006, we recognized a net loss of
$1,362,257 compared to a net loss of $696,066 during the nine months ended March
31,  2005  ($329,003  and $272,204 for the three months ended March 31, 2006 and
2005, respectively). The increase of $666,191 during the nine months ended March
31,  2006,  is  primarily  attributable  to the increase of $235,350 in interest
expense,  as  explained above, the $74,295 loss on the revaluation of derivative
warrants,  explained  below  and  the  increase  of $280,065 in losses of equity
investments.

     Included  in  net  loss applicable to common shareholders for the three and
nine  months  ended  March  31,  2006  is  $1,500,000  related  to  a beneficial
conversion  feature  recorded in connection with the issuance of preferred stock
to Arizcan in February 2006 and the subsequent conversion to common stock during
the  quarter  ended  March  31,  2006.

LIQUIDITY  AND  FINANCIAL  CONDITION

     During  the  nine  months  ended  March  31,  2006, we raised $632,372 cash
through  the  sale of 790,467 shares of our restricted common stock and warrants
to  purchase  746,717  shares  of  our  restricted  common  stock.

     In August 2005, we raised $1,535,000 cash through the exercise of 1,535,000
warrants  with  an  exercise  price  of  $1.00  per  share.

     In  August 2005, we purchased a 50% equity interest in BioAgra for $905,000
cash  (which  includes the $405,000 advanced to Xact Resources during the fiscal
year  ended June 30, 2005) and a note payable of $595,000 which was paid in full
in  September 2005. BioAgra plans to manufacture and sell a beta glucan product,
YBG-2000  to  be marketed as AgraStimTM, to be used as a replacement for hormone
growth  steroids and antibiotics in products such as poultry feed. BioAgra began
producing  and  shipping  product  during  the  quarter  ended  June  30,  2006.


                                       2
<PAGE>
     On  January  19,  2006,  we  completed  the  sale  of 200,000 shares of our
series  A  preferred  stock for $400,000 cash ($200,000 of which was received in
December  2005)  and  an  unsecured  corporate promissory note of $1,100,000. In
February  2006,  Arizcan  converted  the  200,000 shares of preferred stock into
15,000,000  shares  of  the  Company's restricted common stock. Upon conversion,
Arizcan  held  approximately  67%  of  our  issued and outstanding common stock.
During  the  three  months  ended  March  31, 2006, Arizcan made payments on the
promissory  note  totaling  $110,000, with accrued interest of $11,729. On March
31,  2006,  the note had an outstanding balance of $1,005,078, of which $220 was
accrued  interest.  Through  May  2006,  Arizcan  repaid  the  note  in  cash.

     During  the nine months ended March 31, 2006, we used $652,167 in operating
activities.  Net  cash provided by financing activities was $1,851,631; $960,663
was  used  to  pay  notes  payable, $2,167,372 was received from the exercise of
warrants and the issuance of common stock and warrants and $150,000 was received
from  notes  payable.  Net  cash  used  in  investing activities was $1,099,558;
$500,000  was  used  to  purchase  the  51% equity interest in the BioAgra joint
venture  and $875,000 was advanced to BioAgra to support operations and complete
construction  of  the  production  line.  We  had  $125,741  of  cash  and  cash
equivalents  at  March  31,  2006, which is being used to support operations and
activities  of  BioAgra,  in which we own a 50% equity interest. During the nine
months  ended March 31, 2005, we used $453,194 in operating activities, advanced
$225,000 to Xact Resources for the start up of BioAgra, loaned $349,000 to third
parties,  received  $112,801  from the exercise of warrants and common stock and
used  $61,400  to  pay  a  note  payable.

     As  of  March  31,  2006,  if all existing outstanding warrants issued in a
January  2004  private placement were exercised, we will be required to issue an
additional 1,342,500 shares of common stock, and the company, on a fully diluted
basis  (including  the reservation of 832,029 shares as required by the court in
the  Harvest  Court,  LLC  litigation  described  in  Item  1 of Part II of this
report),  would  have  29,353,494 shares of common stock issued and outstanding.

     As  of  March  31, 2006, if the warrants issued to investors in the private
placement  described  above are all exercised, we would receive approximately an
additional  $2,842,500.  However,  no  assurance  can be given that any of these
warrants  will  be  exercised.  If  the  warrants  are exercised, we may use the
additional  funds received to acquire a revenue generating company or to acquire
technology  complementary  to  our current technology, our ownership interest in
ExypnoTech  and  any other licensing agreements or joint venture agreements that
we  may  enter  in  the  future.

     We  intends  to use the funds raised through recent sales of our restricted
common  shares  and  preferred shares to support the operations over the next 12
months. Operational plans include administrative support provided to BioAgra. We
expect  to  receive  funds  from  BioAgra  in the form of payment of outstanding
promissory  notes  and  through payments as specified in the operating agreement
for  BioAgra.  We  initially  plan  to  use such funds to support administrative
activities.  We  continue  to  evaluate  additional  merger  and  acquisition
opportunities.


                                        3
<PAGE>
CRITICAL ACCOUNTING POLICIES

RECENTLY  ISSUED  ACCOUNTING  STANDARD:

In  December  2004,  the Financial Accounting Standards Board (FASB) issued SFAS
No.  123(R), Share-Based Payment, which addresses the accounting for share-based
payment  transactions.  SFAS  No.  123(R)  eliminates the ability to account for
share-based  compensation  transactions  using  APB  25,  and generally requires
instead  that  such transactions be accounted and recognized in the statement of
operations based on their fair value.  SFAS No. 123(R) will be effective for the
Company  beginning  on  July  1,  2006.  Management  is currently evaluating the
provisions  of this standard.  Depending upon the number of and terms of options
that may be granted in future periods, the implementation of this standard could
have  a  significant  impact  on the company's financial position and results of
operations  in  future  periods.

ACCOUNTING  FOR OBLIGATIONS AND INSTRUMENTS POTENTIALLY SETTLED IN THE COMPANY'S
COMMON  STOCK:

     The  company  accounts  for  obligations  and instruments potentially to be
settled  in  the  Company's  own  stock in accordance with EITF Issue No. 00-19,
ACCOUNTING  FOR  DERIVATIVE  FINANCIAL  INSTRUMENTS  INDEXED TO, AND POTENTIALLY
SETTLED IN A COMPANY'S OWN STOCK. This issue addresses the initial balance sheet
classification and measurement of contracts that are indexed to, and potentially
settled  in,  our  own  stock.

     Under  EITF 00-19 contracts are initially classified as equity or as either
assets  or  liabilities, depending on the situation. All contracts are initially
measured  at fair value and subsequently accounted for based on the then current
classification.  Contracts  initially  classified  as  equity  do  not recognize
subsequent  changes  in  fair  value  as  long  as  the contracts continue to be
classified  as  equity.  For  contracts  classified as assets or liabilities, we
report  changes  in  fair  value  in  earnings and disclose these changes in the
financial  statements  as  long  as the contracts remain classified as assets or
liabilities.  If  contracts  classified  as assets or liabilities are ultimately
settled  in  shares,  any previously reported gains or losses on those contracts
continue  to  be  included  in  earnings.  The  classification  of a contract is
reassessed  at  each  balance  sheet  date.

ITEM 3. CONTROLS  AND  PROCEDURES

     We  have  adopted  and maintain disclosure controls and procedures (as such
term  is  defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange
Act  of  1934, as amended (the "Exchange Act")) that are designed to ensure that
information  required  to be disclosed in our reports under the Exchange Act, is
recorded,  processed,  summarized  and reported within the time periods required
under  the  SEC's  rules  and  forms  and  that  the information is gathered and
communicated  to our management, including our Chief Executive Officer and Chief
Financial  Officer,  as  appropriate,  to  allow  for timely decisions regarding
required  disclosure.  In  designing  and evaluating the disclosure controls and
procedures,  management  recognizes  that any controls and procedures, no matter
how  well  designed  and  operated,  can  provide  only  reasonable assurance of
achieving  the  desired  control objectives, and management is required to apply
its  judgment  in  evaluating the cost-benefit relationship of possible controls
and  procedures.

     As  required  by  SEC Rule 15d-15(b), the Company carried out an evaluation
under  the  supervision  and with the participation of our management, including
the  Chief  Executive  Officer (Principal Executive Officer) and Chief Financial
Officer  (Principal  Financial  Officer), of the effectiveness of the design and
operation  of our disclosure controls and procedures as of the end of the period
covered  by this report. Based on the foregoing, our Chief Executive Officer and
Chief  Financial  Officer  have  concluded  that  our  disclosure  controls  and
procedures  are  effective  in  timely  alerting  them  to  material information
required  to  be  included  in  our  periodic  SEC filings. We have not made any
changes in our disclosure controls and procedures or in other factors that could
have  materially  affected  or  are reasonably likely to materially affect those
disclosure  controls  and  procedures  subsequent  to the date of the evaluation
described  above.


                                        4
<PAGE>
                           PART II - OTHER INFORMATION

ITEM 1. Legal  Proceedings

Financing  Agreement  Suit:

In  connection  with  a  financing  obtained  in October 2000, the Company filed
various actions in the United States District Court for the District of Colorado
against,  among others, Harvest Court, LLC, Southridge Capital Investments, LLC,
Daniel  Pickett,  Patricia  Singer and Thomson Kernaghan, Ltd. for violations of
federal  and  state  securities laws, conspiracy, aiding and abetting and common
law  fraud  among  other  claims.  As a result of various procedural rulings, in
January  2002,  the  United  States  District Court for the District of Colorado
transferred  the  case  to  the  United  States  District Court for the Southern
District  of  New  York,  New  York City, New York.  In this litigation, Harvest
Court,  LLC  filed  counterclaims  against  the Company and certain officers and
former  board  members  of the Company, and a number of unrelated third parties.
The  counterclaims  allege violations of federal securities laws and other laws.
Harvest Court, LLC is seeking various forms of relief including compensatory and
punitive  damages.  Responsive  pleadings  have been filed and the litigation is
currently  in  the  discovery  stage.

In  May  2001,  Harvest Court, LLC filed suit against the Company in the Supreme
Court  of  the State of New York, County of New York.  The suit alleges that the
Company  breached  an  October 20, 2000 Stock Purchase Agreement, by not issuing
370,945 free trading shares of the Company's common stock in connection with the
reset  provisions  of  the  Purchase  Agreement due on the second reset date and
approximately  225,012  shares  due  in  connection  with  the third reset date.
Harvest  Court,  LLC  is  seeking  the delivery of such shares or damages in the
alternative.  In August 2001, the Supreme Court of the State of New York, County
of  New York issued a preliminary injunction ordering the Company to reserve and
not  transfer the shares allegedly due to Harvest Court, LLC.  In February 2006,
the  Supreme  Court  of  the  State  of  New  York, County of New York issued an
injunction  ordering  the  Company  to  reserve 3.7% of the Company's issued and
outstanding common stock (832,029 shares at February 13, 2006).  The Company has
set aside and reserved these shares. The Company has filed counterclaims seeking
various  forms  of  relief  against  Harvest  Court,  LLC.


                                        5
<PAGE>
                           PART II - OTHER INFORMATION

ITEM 2. Unregistered  Sales  of  Equity  Securities  and  Use  of  Proceeds

     The  Company  made  the following unregistered sales of its securities from
January  1,  2006  through  March  31,  2006.

<TABLE>
<CAPTION>
DATE OF   TITLE OF       NO. OF
 SALE    SECURITIES      SHARES           CONSIDERATION         CLASS OF PURCHASER
 ----    ----------      ------           -------------         ------------------
----------------------------------------------------------------------------------
<S>      <C>           <C>         <C>                          <C>
 1/5/06  Common Stock      62,500  50,000 for 62,250 shares
         Warrant           62,500  of common stock and          Business Associate
                                   warrant for 62,500 shares
----------------------------------------------------------------------------------
 1/5/06  Common Stock      12,500  10,000 for 12,500 shares
         Warrant           12,500  of common stock and          Business Associate
                                   warrant for 12,500 shares
----------------------------------------------------------------------------------
 1/5/06  Common Stock      12,500  10,000 for 12,500 shares
         Warrant           12,500  of common stock and          Business Associate
                                   warrant for 12,500 shares
----------------------------------------------------------------------------------
 1/5/06  Common Stock      12,500  10,000 for 12,500 shares
         Warrant           12,500  of common stock and a        Business Associate
                                   warrant for 12,500 shares
----------------------------------------------------------------------------------
 1/5/06  Common Stock       6,250  5,000 for 6,250 shares of
         Warrant            6,250  common stock and a warrant   Business Associate
                                   for 6,250 shares
----------------------------------------------------------------------------------
 1/5/06  Common Stock       2,500  2,000 for 2,500 shares of
         Warrant            2,500  common stock and a warrant   Business Associate
                                   for 2,500 shares
----------------------------------------------------------------------------------
1/11/06  Common Stock      12,500  10,000 for 12,500 shares
         Warrant           12,500  of common stock and a        Business Associate
                                   warrant for 12,500 shares
----------------------------------------------------------------------------------
1/12/06  Common Stock      12,500  10,000 for 12,500 shares
         Warrant           12,500  of common stock and a        Business Associate
                                   warrant for 12,500 shares
----------------------------------------------------------------------------------
1/12/06  Common Stock      15,000  12,000 for 15,000 shares
         Warrant           15,000  of common stock and a        Business Associate
                                   warrant for 15,000 shares
----------------------------------------------------------------------------------
 1/6/06  Common Stock      22,500  18,000 for 22,500 shares
         Warrant           22,500  of common stock and a        Business Associate
                                   warrant for 22,500 shares
----------------------------------------------------------------------------------
 1/9/06  Common Stock      31,250  25,000 for 31,250 shares
         Warrant           31,250  of common stock and a        Business Associate
                                   warrant for 31,250 shares
----------------------------------------------------------------------------------
 1/9/06  Common Stock       3,125  2,500 for 3,125 shares of
         Warrant            3,125  common stock and a warrant   Business Associate
                                   for 3,125 shares
----------------------------------------------------------------------------------
 1/9/06  Common Stock       6,250  5,000 for 6,250 shares of
         Warrant            6,250  common stock and a warrant   Business Associate
                                   for 6,250 shares
----------------------------------------------------------------------------------
1/17/06  Common Stock       3,125  2,500 for 3,125 shares of
         Warrant            3,125  common stock and a warrant   Business Associate
                                   for 3,125 shares
----------------------------------------------------------------------------------
1/18/06  Common Stock      18,592  14,872 for 18,592 shares
         Warrant           18,592  of common stock and a        Business Associate
                                   warrant for 18,592 shares
----------------------------------------------------------------------------------
1/18/06  Common Stock      12,500  10,000 for 12,500 shares
         Warrant           12,500  of common stock and a        Business Associate
                                   warrant for 12,500 shares
----------------------------------------------------------------------------------
 2/2/06  Common Stock  15,000,000  Conversion of 200,000
                                   shares of Series A           Business Associate
                                   Preferred Stock
----------------------------------------------------------------------------------
</TABLE>

The warrants have an exercise price of $1.00 per share and a term of 3 years.

Exemption From Registration Claimed


                                        6
<PAGE>
     All of the sales by the Company of its unregistered securities were made by
the  Company  in  reliance  upon  Section 4(2) of the Securities Act of 1933, as
amended  (the  "1933 Act").  All of the individuals and/or entities listed above
that  purchased  the  unregistered  securities  were  almost  all  existing
shareholders,  all known to the Company and its management, through pre-existing
business  relationships,  as  long  standing  business  associates, friends, and
employees.  All  purchasers  were  provided  access to all material information,
which  they  requested, and all information necessary to verify such information
and  were  afforded access to management of the Company in connection with their
purchases.  All  purchasers  of  the  unregistered  securities  acquired  such
securities for investment and not with a view toward distribution, acknowledging
such  intent  to  the  Company. All certificates or agreements representing such
securities  that  were issued contained restrictive legends, prohibiting further
transfer of the certificates or agreements representing such securities, without
such  securities  either  being  first  registered  or  otherwise  exempt  from
registration  in  any  further  resale  or  disposition.

Item 3. Defaults Upon Senior Securities - None.

Item 4. Submission of Masters to a Vote of Security Holders - None.

Item 5. Other Information - None.


                                        7
<PAGE>
Item 6.   EXHIBITS

     (a)  Exhibits.  The  following  is  a  complete  list  of exhibits filed as
          part of this Form 10-QSB. Exhibit numbers correspond to the numbers in
          the  Exhibit  Table  of  Item  601  of  Regulation  S-B.

          Exhibit 11   Computation of Net Loss Per Share

          Exhibit 31.1 Certification of Chief Executive Officer pursuant to
                       Section 302 of the Sarbanes-Oxley Act

          Exhibit 31.2 Certification of Chief Financial Officer pursuant to
                       Section 302 of the Sarbanes-Oxley Act

          Exhibit 32.1 Certification of Principal Executive Officer
                       pursuant to Section 906 of the Sarbanes-Oxley Act

          Exhibit 32.2 Certification of Principal Financial Officer
                       pursuant to Section 906 of the Sarbanes-Oxley Act


                                        8
<PAGE>
                                   SIGNATURES

     In accordance with the requirements of the Securities Exchange Act of 1934,
the  registrant  has  duly  caused this report to be signed on its behalf by the
undersigned,  thereunto  duly  authorized.

                                             VYTA  CORP
                                             (REGISTRANT)

Date:  May  22,  2006                   /s/  Paul  H.  Metzinger
                                        ----------------------------------------
                                        Paul  H.  Metzinger,
                                        President  &  CEO
                                        (Principle Executive Officer)


Date:  May 22, 2006                     /s/ Kristi J. Kampmann
                                        ----------------------------------------
                                        Kristi  J.  Kampmann,
                                        Chief  Financial  Officer
                                        (Principle Financial Officer)


                                        9